HC Wainwright & Co. : The rating of Conrad Biopharmaceuticals (CNTB.US) was maintained, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $8.00.
Zhitong FinanceApr 17 18:40
Connect Biopharma Hldgs Analyst Ratings
BenzingaApr 17 18:37
HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8
BenzingaApr 17 18:40
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
TipRanksApr 17 18:20
Buy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic Partnerships
TipRanksApr 10 14:17
Connect Biopharma Hldgs Analyst Ratings
BenzingaMar 4 20:10
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
TipRanksMar 4 19:31
H.C. Wainwright Starts Connect Biopharma Stock With Buy Rating, $7 Price Target
InvestingMar 4 19:22
Analysts Have Conflicting Sentiments on These Healthcare Companies: Connect Biopharma Holdings (CNTB) and Inspire Medical Systems (INSP)
TipRanksDec 15, 2023 16:51
Cantor Fitzgerald Reiterates Overweight on Connect Biopharma Hldgs, Maintains $5 Price Target
BenzingaSep 13, 2023 20:24
Connect Biopharma Hldgs Analyst Ratings
BenzingaSep 13, 2023 20:23
SVB Securities Remains a Buy on Connect Biopharma Holdings (CNTB)
TipRanksApr 14, 2023 12:57
SVB Securities Adjusts Connect Biopharma Price Target to $7 From $9, Maintains Outperform Rating
MT NewswiresFeb 9, 2023 01:35
Connect Biopharma Hldgs Analyst Ratings
Benzinga Analyst RatingsFeb 8, 2023 21:37
No Data
No Data